Halozyme Thrp (HALO) Stock News

Halozyme Therapeutics (NASDAQ: HALO) has announced its addition to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, 2025, as part of FTSE Russell's annual index reconstitution. The Russell 1000® Index comprises approximately 1,000 of the largest U.S. securities based on market capitalization and serves as a key benchmark for large-cap stock performance.

According to CEO Dr. Helen Torley, this inclusion reflects the company's leadership in rapid large-volume subcutaneous drug delivery and their track record of durable top-and-bottom line growth. The membership in the Russell 1000® Index will remain in place for one year.

Halozyme Therapeutics announced that argenx received European Commission approval for VYVGART with ENHANZE for treating chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. The subcutaneous injection, available as a vial or prefilled syringe, is approved for patients previously treated with corticosteroids or immunoglobulins. VYVGART is notable as the first targeted IgG Fc-antibody fragment for CIDP and represents the first new treatment mechanism in over 30 years. The approval, based on the ADHERE clinical trial results, covers all 27 EU Member States plus Iceland, Norway, and Liechtenstein. This development marks a significant milestone in Halozyme's partnership with argenx and supports the company's growth strategy through expanded European market access.

Halozyme Therapeutics (NASDAQ: HALO) has announced its upcoming participation in two major investor conferences. The company's CEO, Dr. Helen Torley, will attend the Benchmark 2025 Healthcare House Call Virtual Conference on May 29, 2025, for one-on-one meetings. Additionally, she will participate in a fireside chat and investor meetings at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9, 2025, at 7:00 AM PT / 10:00 AM ET.

The presentation at the Goldman Sachs conference will be available via live audio webcast in the Investor Relations section of Halozyme's website, with replays accessible for 90 days after the event.

Halozyme Therapeutics (NASDAQ: HALO) announced that Bristol Myers Squibb has received European Commission approval for a subcutaneous formulation of Opdivo® (nivolumab) developed with Halozyme's ENHANZE® technology. The approval covers multiple adult solid tumor indications and makes Opdivo® the first and only PD-1 inhibitor approved for subcutaneous use in the European Union.

The new formulation allows for a 3-to-5-minute subcutaneous injection, offering a more convenient alternative to traditional administration methods. The approval is supported by the Phase 3 CheckMate -67T trial and is valid across all 27 EU member states, plus Iceland, Liechtenstein and Norway. This follows the U.S. FDA approval of Opdivo Qvantig™ in December 2024.

Halozyme (NASDAQ: HALO) reported strong Q1 2025 results and raised its 2025 financial guidance. Total revenue increased 35% YOY to $265 million, with royalty revenue up 39% to $168 million. Net income grew 54% to $118 million, and GAAP diluted EPS rose 55% to $0.93. The company announced a new $250 million share repurchase program. Halozyme raised its 2025 guidance, projecting total revenue of $1,200-$1,280 million (18-26% YOY growth), royalty revenue of $750-785 million, and adjusted EBITDA of $790-840 million. Growth was driven by strong performance of blockbuster brands including Darzalex SC, Phesgo, and VYVGART Hytrulo, along with four recently launched products. The company also filed a patent infringement lawsuit against Merck regarding SC Keytruda development.

Halozyme Therapeutics (NASDAQ: HALO) announced that its President and CEO, Dr. Helen Torley, will present at the upcoming BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET. The company will provide a live audio webcast of the presentation on their Investor Relations website, with replays available for 90 days after the conference.

Halozyme Therapeutics (NASDAQ: HALO) has announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, after market close. The company will host a conference call the same day at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. Investors can access the call through pre-registration and join the live webcast through the Investors section of Halozyme's corporate website.

Halozyme Therapeutics (NASDAQ: HALO) announced that argenx received a positive CHMP opinion recommending European Commission approval for VYVGART® with ENHANZE® for chronic inflammatory demyelinating polyneuropathy (CIDP) treatment. The subcutaneous injection, available as a vial or prefilled syringe, is designed for adult patients with progressive or relapsing active CIDP after prior treatment with corticosteroids or immunoglobulins.

VYVGART represents the first targeted IgG Fc-antibody fragment for CIDP and the first novel mechanism of action in over 30 years. The recommendation is based on the ADHERE clinical trial, the largest CIDP patient study to date. The European Commission's decision, expected within two months, will apply to all 27 EU Member States plus Iceland, Norway, and Liechtenstein.

Halozyme Therapeutics (NASDAQ: HALO) has filed a patent infringement lawsuit against Merck in U.S. District Court in New Jersey over the subcutaneous formulation of Keytruda. The complaint alleges that Merck's subcutaneous (SC) Keytruda infringes multiple patents related to Halozyme's MDASE technology, which were filed beginning in 2011.

The lawsuit comes as Merck plans to launch SC Keytruda in 2025 following completed phase 3 clinical testing. Halozyme claims Merck developed the SC formulation without permission, despite being aware of Halozyme's patents. The company is seeking damages and injunctive relief to stop the infringement.

Importantly, the disputed MDASE patent rights are separate from Halozyme's ENHANZE® licensing program and will not impact existing licensees or related revenues. The patents stem from Halozyme's research involving nearly 7,000 modifications to human hyaluronidases, which enable rapid subcutaneous administration of therapeutic drugs.